Last updated on November 2017

Rituximab plus Belimumab for Lupus Nephritis (CALIBRATE Study)

Brief description of study

Rituximab plus Belimumab for Lupus Nephritis (CALIBRATE Study)

Detailed Study Description

Lupus nephritis is a severe form of systemic lupus erythematosus (SLE) with active disease in the kidneys. SLE is a complex disease in which the body's own immune system attacks some of the body parts: the skin, the joints, the kidneys, the nervous system, the heart, the lungs and the blood. Treatment for SLE usually involves drugs that are designed to block the immune system attacks. When SLE affects the kidneys (nephritis), stronger immune suppressing treatment is usually needed.

In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.

For more information, visit

Clinical Study Identifier: TX2990

Contact Investigators or Research Sites near you

Start Over

Karla Caylor

Emory University
Atlanta, GA USA

Lidia Espino

University of California, San Francisco
San Francisco, CA USA

Sanita Kandasami

Feinstein Institute
Manhasset, NY USA

Azza Badr

University of Texas, Southwestern
Dallas, TX USA

Sarah Hasselbach

Ohio State University
Columbus, OH USA

Nicole Kaiden

New York University - Langone Medical Center
New York, NY USA

Miya Okado

Columbia University
New York, NY USA

Kerri Merritt

Hospital for Special Surgery
New York, NY USA

Mia Vasquez-Gutierrez

University of California, Los Angeles 
Los Angeles, CA USA

Ruth Grosskreuz

University of Colorado, Denver
Aurora, CO USA

Courtney Newbold

Colorado Kidney Care
Denver, CO USA